OPR - Delayed Quote • USD RVPH Jan 2026 5.500 call (RVPH260116C00005500) Follow 1.6600 0.0000 (0.00%) At close: January 16 at 3:35 PM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for RVPH260116C00005500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: RVPH RVPH: Full Year 2023 Results Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights RVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER Data Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting Reviva to Present at the UBS Virtual CNS Day Reviva to Present at the 36th Annual ROTH Conference Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
